Nordic Nanovector ASA announces that full results from its Phase 2 clinical trials of Betalutin® in resistant/refractory indolent non-Hodgkin’s lymphoma have been published at EudraCT, the European Union Drug Regulating Authorities Clinical Trials Database of the European Union.
